Non small cell lung cancer (NSCLC) xenografts as models for the prediction of response to tyrosine kinase inhibitors

被引：0
|
作者：
Fichtner, Iduna [1 ]
Rolff, Jana [1 ]
Soong, Richie [2 ]
Becker, Michael [1 ]
Lee, Sumarlin [2 ]
Sommer, Anette [3 ]
Merk, Johannes [4 ]
机构：
[1] Max Delbruck Ctr, Berlin 117548, Germany
[2] Natl Univ Singapore, Singapore, Singapore
[3] Bayer Schering Pharma AG, Berlin, Germany
[4] Lung Clin, Berlin, Germany
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3528S / 3528S
页数：1
相关论文
共 50 条
  • [41] Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib
    Dediu, Mircea
    Median, Dragos
    Alexandru, Aurelia
    Vremes, Georgeta
    Gal, Cristian
    [J]. JOURNAL OF BUON, 2007, 12 : S137 - S149
  • [42] Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
    Asami, Kazuhiro
    Atagi, Shinji
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (04): : 646 - 659
  • [43] Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer
    Franco, Fernando
    Provencio, Mariano
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 (10) : 4092 - 4095
  • [44] Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
    Scagliotti, Giorgio
    Govindan, Ramaswamy
    [J]. ONCOLOGIST, 2010, 15 (05): : 436 - 446
  • [45] Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer
    Lampaki, Sofia
    Lazaridis, George
    Zarogoulidis, Konstantinos
    Kioumis, Ioannis
    Papaiwannou, Antonis
    Tsirgogianni, Katerina
    Karavergou, Anastasia
    Tsiouda, Theodora
    Karavasilis, Vasilis
    Yarmus, Lonny
    Darwiche, Kaid
    Freitag, Lutz
    Sakkas, Antonios
    Kantzeli, Angeliki
    Baka, Sofia
    Hohenforst-Schmidt, Wolfgang
    Zarogoulidis, Paul
    [J]. JOURNAL OF CANCER, 2015, 6 (06): : 568 - 574
  • [46] Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
    Vasileios S. Skouras
    Charis Maragkos
    Dimitra Grapsa
    Konstantinos N. Syrigos
    [J]. BioDrugs, 2016, 30 : 421 - 439
  • [47] Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors
    Wrona, Anna
    Dziadziuszko, Rafal
    Jassem, Jacek
    [J]. CANCER TREATMENT REVIEWS, 2018, 71 : 59 - 67
  • [48] Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
    Krawczyk, Pawel
    Mlak, Radoslaw
    Powrozek, Tomasz
    Nicos, Marcin
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (05): : 401 - 406
  • [49] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CO-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND RESPONSE TO EGFR TYROSINE KINASE INHIBITORS (TKIS)
    Barnet, Megan B.
    O'Toole, Sandra
    Horvath, Lisa' G.
    Selinger, Christina
    Yu, Bing
    Trent, Ronald
    Ng, Chiu Chin
    Boyer, Michael J.
    Cooper, Wendy
    Kao, Steven
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 156 - 156
  • [50] Role of late response evaluation in Non Small Cell Lung Cancer (NSCLC) treated with EGFR Tyrosine Kinase Inhibitor with PET quantitative parameters
    Bhoil, A.
    Mittal, B.
    Singh, N.
    Singh, B.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S307 - S308
12345